Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$36.72 USD
+0.21 (0.58%)
Updated May 24, 2024 04:00 PM ET
After-Market: $36.70 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Biohaven Ltd. [BHVN]
Reports for Purchase
Showing records 61 - 80 ( 268 total )
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 12/10/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Second Phase 3 Confirms Zavegepant?s Best-in-Class Onset of Action Clearing Way for 1Q21 Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Zavegepant Shoots Towards Registration As CFO Engelhart Retires
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 11/19/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 11/12/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Pfizer Collaboration Expands Nurtec?s Reach Around the Globe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
BHVN Inks PFE Collaboration Deal Ahead of Ex-US Efforts
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 10/22/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 10/15/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Biotechnology-Weekly Neurology Prescription Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Nurtec Market Leadership Translates to Earnings Beat in 3Q Prerelease; Reiterate Buy, PT to $160
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
No Such Thing As Too Much Of A Good Thing - BHVN Announces 3Q21 Nurtec Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
3Q21 Commercial Biotech Preview: Will We See Tricks or Treats in 3Q21 Earnings?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 9/24/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Verdiperstat Comes Up Short in MSA Phase 3, Though Bull Thesis Remains Unchanged; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D